focus -WSS

focus

author：comprehensive 2025-10-03 00:22:10 - browse：686

Sage Therapeutics, a biotech developing an experimental treatment for postpartum depression, this week trumpeted strong results from a clinical trial, which cheered investors and pushed up its stock price. But outside the lab, the company’s aggressive efforts to raise awareness of postpartum depression have proved divisive.

The campaign’s message: “When it comes to postpartum depression, silence sucks.” It features close-up photos of distressed, tearful women who can’t speak — because they have pacifiers stuck in their mouths.

The images have been plastered on bus stops, buses, conference booths, and on a dedicated website. The ads don’t specifically mention Sage’s drug, which still needs further testing before the company can bring it to the Food and Drug Administration for possible approval. Instead, they urge women to talk “openly and honestly” about postpartum depression. An estimated 600,000 women in the U.S. alone experience symptoms, which range from insomnia and irritability to difficulty bonding with their baby.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： HHS names first

leisure time

WSS

Affordable Connectivity Program vital to health care, experts say

Heart disease and mental health: A look at cardiac psychology

New England Journal of Medicine addresses racist history, slavery

I learned firsthand about improving diversity in clinical trials

Vir antibody drug aimed at influenza A fails in clinical trial

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

hotspot

focus

knowledge

Trump demands the U.S. pay no more for drugs than other countries … again

How I ended up pumping milk in a bathroom stall at JPM 2024

Guidelines to prevent youth baseball injuries need more muscle

I learned firsthand about improving diversity in clinical trials

The cancer drug shortage isn’t new — and neither are the solutions

DeSantis can now import cheaper drugs. But will Biden get credit?

Activists slam private health insurers over coverage restrictions

Readout LOUD podcast: live from JPM 2024

BioMarin wins approval for gene therapy to treat hemophilia A

Winning ticket for $1 billion Powerball jackpot sold in California

leisure time

Vir antibody drug aimed at influenza A fails in clinical trial

Vir antibody drug aimed at influenza A fails in clinical trial

Heart disease and mental health: A look at cardiac psychology

Study identifies new proteins linked to dementia risk 25 years later

Idaho abortion case may prompt more restrictions in other states

Why Congress must ban federal programs from using QALYs

Wikipedia

leisure time

focus

leisure time